VEN combined with azacitidine

DRUG2 trials

Conditions

Acute Myeloid LeukemiaIDH1 MutationIDH2 MutationNPM1 MutationVenetoclax Combined With AzacitidineVenetoclax Combined With Azacitidine Plus Homoharringtonine

Phase 2

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Not yet recruitingNCT07664839

Shen yangAcute Myeloid Leukemia, IDH1 Mutation, IDH2 Mutation +1

Start: 2026-07-01End: 2032-05-31Target: 148Updated: 2026-06-24

Phase 3

VAH Versus VA for Salvage Therapy of R/R-AML

NCT05457361

Nanfang Hospital, Southern Medical UniversityVenetoclax Combined With Azacitidine, Venetoclax Combined With Azacitidine Plus Homoharringtonine

Start: 2022-03-01End: 2023-12-31Target: 162Updated: 2022-07-14

VEN combined with azacitidine

Sponsors

Conditions

Phase 2

Phase 3